Cargando…

A large real-world cohort study of examined lymph node standards for adequate nodal staging in early non-small cell lung cancer

BACKGROUND: The current National Comprehensive Cancer Network (NCCN) guidelines for non-small cell lung cancer (NSCLC) recommend that surgeons sample is not clear. We aimed to define a minimal number of examined lymph nodes for removal or sampling for optimized nodal staging recommendation, with a f...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Zhihua, Song, Zhengbo, Jiao, Wenjie, Mei, Weijian, Xu, Chunwei, Huang, Qinghua, An, Chaolun, Shi, Jianguang, Wang, Wenxian, Yu, Guiping, Sun, Pingli, Zhang, Yinbin, Shen, Jianfei, Song, Yong, Qian, Jun, Yao, Wang, Yang, Han
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947406/
https://www.ncbi.nlm.nih.gov/pubmed/33718024
http://dx.doi.org/10.21037/tlcr-20-1024
_version_ 1783663219550715904
author Zhu, Zhihua
Song, Zhengbo
Jiao, Wenjie
Mei, Weijian
Xu, Chunwei
Huang, Qinghua
An, Chaolun
Shi, Jianguang
Wang, Wenxian
Yu, Guiping
Sun, Pingli
Zhang, Yinbin
Shen, Jianfei
Song, Yong
Qian, Jun
Yao, Wang
Yang, Han
author_facet Zhu, Zhihua
Song, Zhengbo
Jiao, Wenjie
Mei, Weijian
Xu, Chunwei
Huang, Qinghua
An, Chaolun
Shi, Jianguang
Wang, Wenxian
Yu, Guiping
Sun, Pingli
Zhang, Yinbin
Shen, Jianfei
Song, Yong
Qian, Jun
Yao, Wang
Yang, Han
author_sort Zhu, Zhihua
collection PubMed
description BACKGROUND: The current National Comprehensive Cancer Network (NCCN) guidelines for non-small cell lung cancer (NSCLC) recommend that surgeons sample is not clear. We aimed to define a minimal number of examined lymph nodes for removal or sampling for optimized nodal staging recommendation, with a focus on T(1–3)N(0)M(0) patients. METHODS: A total of 55,101 consecutive patients were selected, including 52,099 patients with US Surveillance, Epidemiology, and End Results (SEER) data and 3,002 patients in a Chinese multicenter database from 11 thoracic referral centers, who underwent complete resection plus lymph node dissection or sampling for stage T(1–3)N(0)M(0) NSCLC. Propensity score-matching analysis was performed with R software, and a cut-off value was calculated using X-tile software. Survival was evaluated using the Kaplan-Meier method and Cox proportional hazard models. RESULTS: Five-year survival rates with respect to total examined lymph nodes numbers (examined lymph nodes <10 vs. examined lymph nodes ≥10) were 69% and 64% (group A), 66% and 63% (group B), 62% and 58% (group C), 81% and 75% (group D). There were significant differences between examined lymph nodes <10 and examined lymph nodes >10 in each group (P<0.001). CONCLUSIONS: A minimum of 10 examined lymph nodes would significantly improve T(1–3)N(0)M(0) NSCLC prognosis and patients’ survival rates if implemented as a minimum standard for lymphadenectomy. Therefore, we recommended a minimum of 10 examined lymph nodes for T(1–3)N(0)M(0) patients.
format Online
Article
Text
id pubmed-7947406
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-79474062021-03-12 A large real-world cohort study of examined lymph node standards for adequate nodal staging in early non-small cell lung cancer Zhu, Zhihua Song, Zhengbo Jiao, Wenjie Mei, Weijian Xu, Chunwei Huang, Qinghua An, Chaolun Shi, Jianguang Wang, Wenxian Yu, Guiping Sun, Pingli Zhang, Yinbin Shen, Jianfei Song, Yong Qian, Jun Yao, Wang Yang, Han Transl Lung Cancer Res Original Article BACKGROUND: The current National Comprehensive Cancer Network (NCCN) guidelines for non-small cell lung cancer (NSCLC) recommend that surgeons sample is not clear. We aimed to define a minimal number of examined lymph nodes for removal or sampling for optimized nodal staging recommendation, with a focus on T(1–3)N(0)M(0) patients. METHODS: A total of 55,101 consecutive patients were selected, including 52,099 patients with US Surveillance, Epidemiology, and End Results (SEER) data and 3,002 patients in a Chinese multicenter database from 11 thoracic referral centers, who underwent complete resection plus lymph node dissection or sampling for stage T(1–3)N(0)M(0) NSCLC. Propensity score-matching analysis was performed with R software, and a cut-off value was calculated using X-tile software. Survival was evaluated using the Kaplan-Meier method and Cox proportional hazard models. RESULTS: Five-year survival rates with respect to total examined lymph nodes numbers (examined lymph nodes <10 vs. examined lymph nodes ≥10) were 69% and 64% (group A), 66% and 63% (group B), 62% and 58% (group C), 81% and 75% (group D). There were significant differences between examined lymph nodes <10 and examined lymph nodes >10 in each group (P<0.001). CONCLUSIONS: A minimum of 10 examined lymph nodes would significantly improve T(1–3)N(0)M(0) NSCLC prognosis and patients’ survival rates if implemented as a minimum standard for lymphadenectomy. Therefore, we recommended a minimum of 10 examined lymph nodes for T(1–3)N(0)M(0) patients. AME Publishing Company 2021-02 /pmc/articles/PMC7947406/ /pubmed/33718024 http://dx.doi.org/10.21037/tlcr-20-1024 Text en 2021 Translational Lung Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Zhu, Zhihua
Song, Zhengbo
Jiao, Wenjie
Mei, Weijian
Xu, Chunwei
Huang, Qinghua
An, Chaolun
Shi, Jianguang
Wang, Wenxian
Yu, Guiping
Sun, Pingli
Zhang, Yinbin
Shen, Jianfei
Song, Yong
Qian, Jun
Yao, Wang
Yang, Han
A large real-world cohort study of examined lymph node standards for adequate nodal staging in early non-small cell lung cancer
title A large real-world cohort study of examined lymph node standards for adequate nodal staging in early non-small cell lung cancer
title_full A large real-world cohort study of examined lymph node standards for adequate nodal staging in early non-small cell lung cancer
title_fullStr A large real-world cohort study of examined lymph node standards for adequate nodal staging in early non-small cell lung cancer
title_full_unstemmed A large real-world cohort study of examined lymph node standards for adequate nodal staging in early non-small cell lung cancer
title_short A large real-world cohort study of examined lymph node standards for adequate nodal staging in early non-small cell lung cancer
title_sort large real-world cohort study of examined lymph node standards for adequate nodal staging in early non-small cell lung cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947406/
https://www.ncbi.nlm.nih.gov/pubmed/33718024
http://dx.doi.org/10.21037/tlcr-20-1024
work_keys_str_mv AT zhuzhihua alargerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer
AT songzhengbo alargerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer
AT jiaowenjie alargerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer
AT meiweijian alargerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer
AT xuchunwei alargerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer
AT huangqinghua alargerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer
AT anchaolun alargerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer
AT shijianguang alargerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer
AT wangwenxian alargerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer
AT yuguiping alargerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer
AT sunpingli alargerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer
AT zhangyinbin alargerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer
AT shenjianfei alargerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer
AT songyong alargerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer
AT qianjun alargerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer
AT yaowang alargerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer
AT yanghan alargerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer
AT alargerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer
AT zhuzhihua largerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer
AT songzhengbo largerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer
AT jiaowenjie largerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer
AT meiweijian largerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer
AT xuchunwei largerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer
AT huangqinghua largerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer
AT anchaolun largerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer
AT shijianguang largerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer
AT wangwenxian largerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer
AT yuguiping largerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer
AT sunpingli largerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer
AT zhangyinbin largerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer
AT shenjianfei largerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer
AT songyong largerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer
AT qianjun largerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer
AT yaowang largerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer
AT yanghan largerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer
AT largerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer